Literature DB >> 22802026

[Therapy refractory polyarthritis and fever].

M Licht1, U Kyank, C Kneitz.   

Abstract

Primary manifestation of an autoinflammatory systemic disease was found in a 15-year-old patient, which initially ran a fulminant course. The course was first controlled by therapy with steroids and cyclosporin A. In the course of the disease, the patient developed a therapy refractory polyarthritis, which failed to respond to a combination of disease-modifying antirheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors. A good disease control could only be achieved with an interleukin 6 (IL-6) blockade and DMARDs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22802026     DOI: 10.1007/s00393-012-0989-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  4 in total

Review 1.  Diagnosis and management of juvenile idiopathic arthritis.

Authors:  Femke H M Prince; Marieke H Otten; Lisette W A van Suijlekom-Smit
Journal:  BMJ       Date:  2010-12-03

Review 2.  Juvenile idiopathic arthritis.

Authors:  Berent Prakken; Salvatore Albani; Alberto Martini
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

3.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

4.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.